A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?
Brain metastases
Breast cancer
Concordance
Genetic alterations
Leptomeningeal metastases
Liquid biopsy
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
19
12
2022
accepted:
07
02
2023
medline:
30
3
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
Acquired mutations or altered gene expression patterns in brain metastases (BM) and/or leptomeningeal metastases (LM) of breast cancer may play a role in therapy-resistance and offer new molecular targets and treatment options. Despite expanding knowledge of genetic alterations in breast cancer and their metastases, clinical applications for patients with central nervous system (CNS) metastases are currently limited. An emerging tool are DNA-techniques that may detect genetic alterations of the CNS metastases in the cerebrospinal fluid (CSF). In this review we discuss genetic studies in breast cancer and CNS metastases and the role of liquid biopsies in CSF.
Identifiants
pubmed: 36820955
doi: 10.1007/s11060-023-04261-2
pii: 10.1007/s11060-023-04261-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-13Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655
doi: 10.1158/1078-0432.CCR-06-2478
pubmed: 17363517
Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 22:2865–2872. https://doi.org/10.1200/JCO.2004.12.149
doi: 10.1200/JCO.2004.12.149
pubmed: 15254054
Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617
doi: 10.1200/JCO.2004.01.175
pubmed: 15337811
Wang N, Bertalan MS, Brastianos PK (2018) Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124:21–35. https://doi.org/10.1002/cncr.30911
doi: 10.1002/cncr.30911
pubmed: 29165794
Schrijver WAME, Suijkerbuijk KPM, Van Gils CH et al (2018) Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst 110:568–580
doi: 10.1093/jnci/djx273
pubmed: 29315431
Hulsbergen AFC, Claes A, Kavouridis VK et al (2020) Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. https://doi.org/10.1093/neuonc/noaa013
doi: 10.1093/neuonc/noaa013
pubmed: 31970416
pmcid: 7651667
Cardoso F, Senkus E, Costa A et al (2018) 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol 29:1634–1657. https://doi.org/10.1093/annonc/mdy192
doi: 10.1093/annonc/mdy192
pubmed: 30032243
Lin NU, Borges V, Anders C et al (2020) Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 38:2610–2619. https://doi.org/10.1200/JCO.20.00775
doi: 10.1200/JCO.20.00775
pubmed: 32468955
pmcid: 7403000
Pérez-García JM, Batista MV, Cortez P et al (2022) Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. https://doi.org/10.1093/NEUONC/NOAC144
doi: 10.1093/NEUONC/NOAC144
pmcid: 9825345
Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164–1177. https://doi.org/10.1158/2159-8290.CD-15-0369
doi: 10.1158/2159-8290.CD-15-0369
pubmed: 26410082
pmcid: 4916970
Turashvili G, Brogi E (2017) Tumor heterogeneity in breast cancer. Front Med 4:227. https://doi.org/10.3389/fmed.2017.00227
doi: 10.3389/fmed.2017.00227
Tarin D (2008) Comparisons of metastases in different organs: biological and clinical implications. Clin Cancer Res 14:1923–1925
doi: 10.1158/1078-0432.CCR-07-5259
pubmed: 18381928
Morgan AJ, Giannoudis A, Palmieri C (2021) The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30556-8
doi: 10.1016/S1470-2045(20)30556-8
pubmed: 34339644
Bertucci F, Ng CKY, Patsouris A et al (2019) Genomic characterization of metastatic breast cancers. Nature 569:560–564. https://doi.org/10.1038/s41586-019-1056-z
doi: 10.1038/s41586-019-1056-z
pubmed: 31118521
Angus L, Smid M, Wilting SM et al (2019) The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet 51:1450–1458. https://doi.org/10.1038/s41588-019-0507-7
doi: 10.1038/s41588-019-0507-7
pubmed: 31570896
pmcid: 6858873
Huang RSP, Haberberger J, Mcgregor K et al (2021) Clinicopathologic and genomic landscape of breast carcinoma brain metastases. Oncologist. https://doi.org/10.1002/onco.13855
doi: 10.1002/onco.13855
pubmed: 34431578
pmcid: 8571774
Giannoudis A, Sartori A, Eastoe L et al (2021) Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. Breast Cancer Res Treat 190:241–253. https://doi.org/10.1007/S10549-021-06364-8
doi: 10.1007/S10549-021-06364-8
pubmed: 34499316
pmcid: 8558178
Da Silva L, Simpson PT, Smart CE et al (2010) HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 12:R46. https://doi.org/10.1186/bcr2603
doi: 10.1186/bcr2603
pubmed: 20604919
pmcid: 2949633
Wikman H, Lamszus K, Detels N et al (2012) Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 14:R49. https://doi.org/10.1186/BCR3150
doi: 10.1186/BCR3150
pubmed: 22429330
pmcid: 3446383
Lee JY, Park K, Lim SH et al (2015) Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget 6:43731–43742. https://doi.org/10.18632/oncotarget.6192
doi: 10.18632/oncotarget.6192
pubmed: 26527317
pmcid: 4791262
Bollig-Fischer A, Michelhaugh SK, Wijesinghe P et al (2015) Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget 6:14614–14624. https://doi.org/10.18632/oncotarget.3786
doi: 10.18632/oncotarget.3786
pubmed: 25970776
pmcid: 4546491
Schrijver WA, Selenica P, Lee JY et al (2018) Mutation profiling of key cancer genes in primary breast cancers and their distant metastases. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-17-2310
doi: 10.1158/0008-5472.CAN-17-2310
pubmed: 29615433
pmcid: 6355142
De Mattos-Arruda L, Ng CKY, Piscuoglio S et al (2018) Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget 9:20617–20630. https://doi.org/10.18632/oncotarget.25041
doi: 10.18632/oncotarget.25041
pubmed: 29755676
pmcid: 5945519
Tyran M, Carbuccia N, Garnier S et al (2019) A comparison of DNA mutation and copy number profiles of primary breast cancers and paired brain metastases for identifying clinically relevant genetic alterations in brain metastases. Cancers (Basel). https://doi.org/10.3390/CANCERS11050665
doi: 10.3390/CANCERS11050665
pubmed: 31086113
Thulin A, Andersson C, Werner Rönnerman E et al (2021) Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. Sci Rep 11:23548. https://doi.org/10.1038/s41598-021-02903-x
doi: 10.1038/s41598-021-02903-x
pubmed: 34876602
pmcid: 8651781
Gao R, Davis A, McDonald TO et al (2016) Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet 48:1119–1130. https://doi.org/10.1038/ng.3641
doi: 10.1038/ng.3641
pubmed: 27526321
pmcid: 5042845
Magbanua MJM, Melisko M, Roy R et al (2013) Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res 73:7134–7143. https://doi.org/10.1158/0008-5472.CAN-13-2051
doi: 10.1158/0008-5472.CAN-13-2051
pubmed: 24142343
De M-A, Mayor R, Ng CKY et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. https://doi.org/10.1038/ncomms9839
doi: 10.1038/ncomms9839
pubmed: 26554728
pmcid: 5426516
White MD, Klein RH, Shaw B et al (2021) Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Netw Open. https://doi.org/10.1001/jamanetworkopen.2021.20040
doi: 10.1001/jamanetworkopen.2021.20040
pubmed: 34792593
pmcid: 8603088
Fitzpatrick A, Iravani M, Mills A et al (2022) Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis. Clin Cancer Res 28:1180–1191. https://doi.org/10.1158/1078-0432.CCR-21-3017
doi: 10.1158/1078-0432.CCR-21-3017
pubmed: 34921020
pmcid: 7612501
Boire A, Brandsma D, Brastianos PK et al (2019) Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 21:571–583. https://doi.org/10.1093/neuonc/noz012
doi: 10.1093/neuonc/noz012
pubmed: 30668804
pmcid: 6502489
Cheok SK, Narayan A, Arnal-Estape A et al (2021) Tumor DNA mutations from intraparenchymal brain metastases are detectable in CSF. JCO Precis Oncol. https://doi.org/10.1200/PO.20.00292
doi: 10.1200/PO.20.00292
pubmed: 34250381
pmcid: 8232069
Lee JH, Menzies AM, Carlino MS et al (2020) Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-3926
doi: 10.1158/1078-0432.CCR-19-3926
pubmed: 33334906
pmcid: 7956224
Pentsova EI, Shah RH, Tang J et al (2016) Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 34:2404–2415. https://doi.org/10.1200/JCO.2016.66.6487
doi: 10.1200/JCO.2016.66.6487
pubmed: 27161972
pmcid: 4981784
Ma C, Yang X, Xing W et al (2020) Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Thoracic Cancer. https://doi.org/10.1111/1759-7714.13300
doi: 10.1111/1759-7714.13300
pubmed: 33354921
pmcid: 7882384
von Baumgarten L, Kumbrink J, Jung A et al (2020) Therapeutic management of neuro-oncologic patients—potential relevance of CSF liquid biopsy. Theranostics 10:856–866. https://doi.org/10.7150/thno.36884
doi: 10.7150/thno.36884
Siravegna G, Geuna E, Mussolin B et al (2017) Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open 2:e00253. https://doi.org/10.1136/esmoopen-2017-000253
doi: 10.1136/esmoopen-2017-000253
Li X, Zhang Y, Ding J et al (2018) Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis. Oncotarget. https://doi.org/10.18632/oncotarget.23597
doi: 10.18632/oncotarget.23597
pubmed: 30701027
pmcid: 6340874
Carausu M, Melaabi S, Pierga J-Y et al (2020) ESR1 mutation detection and dynamics in meningeal carcinomatosis in breast cancer. J Breast Cancer 23:218. https://doi.org/10.4048/jbc.2020.23.e4
doi: 10.4048/jbc.2020.23.e4
pubmed: 32395380
Angus L, Deger T, Jager A et al (2021) Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-3954
doi: 10.1158/1078-0432.CCR-20-3954
pubmed: 33514525
Shah M, Takayasu T, Zorofchian Moghadamtousi S et al (2021) Evaluation of the oncomine pan-cancer cell-free assay for analyzing circulating tumor DNA in the cerebrospinal fluid in patients with central nervous system malignancies. J Mol Diagnostics 23:171–180. https://doi.org/10.1016/j.jmoldx.2020.10.013
doi: 10.1016/j.jmoldx.2020.10.013
Chandarlapaty S, Chen D, He W et al (2016) Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer. JAMA Oncol 2:1310. https://doi.org/10.1001/jamaoncol.2016.1279
doi: 10.1001/jamaoncol.2016.1279
pubmed: 27532364
pmcid: 5063698
Razavi P, Chang MT, Xu G et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34:427-438.e6. https://doi.org/10.1016/J.CCELL.2018.08.008
doi: 10.1016/J.CCELL.2018.08.008
pubmed: 30205045
pmcid: 6327853
Fitzgerald DM, Muzikansky A, Pinto C et al (2019) Association between PIK3CA mutation status and development of brain metastases in HR+/HER2− metastatic breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdz242.013
doi: 10.1093/annonc/mdz242.013
Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K Pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402. https://doi.org/10.1016/j.ccr.2007.08.030
doi: 10.1016/j.ccr.2007.08.030
pubmed: 17936563
Pascual J, Turner NC (2019) Targeting the PI3-kinase pathway in triple negative breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdz133
doi: 10.1093/annonc/mdz133
pubmed: 31050709
pmcid: 6594455
Batalini F, Moulder SL, Winer EP et al (2020) Response of brain metastases from PIK3CA -Mutant breast cancer to alpelisib. JCO Precis Oncol. https://doi.org/10.1200/po.19.00403
doi: 10.1200/po.19.00403
pubmed: 35050731
pmcid: 7446424
Formisano L, Lu Y, Servetto A et al (2019) Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. https://doi.org/10.1038/S41467-019-09068-2
doi: 10.1038/S41467-019-09068-2
pubmed: 30914635
pmcid: 6435685
Meric-Bernstam F, Bahleda R, Hierro C et al (2022) Futibatinib, an irreversible FGFR1-4 Inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase i dose-expansion study. Cancer Discov 12:402–415. https://doi.org/10.1158/2159-8290.CD-21-0697
doi: 10.1158/2159-8290.CD-21-0697
pubmed: 34551969
Kodack DP, Askoxylakis V, Ferraro GB et al (2017) The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med. https://doi.org/10.1126/SCITRANSLMED.AAL4682
doi: 10.1126/SCITRANSLMED.AAL4682
pubmed: 28539475
pmcid: 5917603
Saunus J, McCart Reed A, Lim Z, Lakhani S (2017) Breast cancer brain metastases: clonal evolution in clinical context. Int J Mol Sci 18:152. https://doi.org/10.3390/ijms18010152
doi: 10.3390/ijms18010152
pubmed: 28098771
pmcid: 5297785
Seoane J, De Mattos-Arruda L, Le Rhun E et al (2019) Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol Off J Eur Soc Med Oncol 30:211–218. https://doi.org/10.1093/annonc/mdy544
doi: 10.1093/annonc/mdy544
Pan W, Gu W, Nagpal S et al (2015) Brain tumor mutations detected in cerebral spinal fluid. Clin Chem 61:514–522. https://doi.org/10.1373/clinchem.2014.235457
doi: 10.1373/clinchem.2014.235457
pubmed: 25605683
pmcid: 5412506